BusinessZynerba Pharmaceuticals Provides 2018 Clinical and Corporate UpdateBy Nasdaq OMXJan 3, 2018, 9:30 PM UTC
BusinessZynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X SyndromeBy Nasdaq OMXSep 28, 2017, 10:30 AM UTC
BusinessCannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric FluidBy Nasdaq OMXApr 12, 2016, 11:00 AM UTC
